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Abstract
Background—During late summer/fall 2014, pediatric cases of acute flaccid myelitis (AFM) 
occurred in the United States, coincident with a national outbreak of enterovirus D68 (EV-D68)–
associated severe respiratory illness.
Methods—Clinicians and health departments reported standardized clinical, epidemiologic, and 
radiologic information on AFM cases to the Centers for Disease Control and Prevention (CDC), 
and submitted biological samples for testing. Cases were ≤21 years old, with acute onset of limb 
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weakness 1 August–31 December 2014 and spinal magnetic resonance imaging (MRI) showing 
lesions predominantly restricted to gray matter.
Results—From August through December 2014, 120 AFM cases were reported from 34 states. 
Median age was 7.1 years (interquartile range, 4.8–12.1 years); 59% were male. Most experienced 
respiratory (81%) or febrile (64%) illness before limb weakness onset. MRI abnormalities were 
predominantly in the cervical spinal cord (103/118). All but 1 case was hospitalized; none died. 
Cerebrospinal fluid (CSF) pleocytosis (>5 white blood cells/μL) was common (81%). At CDC, 1 
CSF specimen was positive for EV-D68 and Epstein-Barr virus by real-time polymerase chain 
reaction, although the specimen had >3000 red blood cells/μL. The most common virus detected 
in upper respiratory tract specimens was EV-D68 (from 20%, and 47% with specimen collected ≤7 
days from respiratory illness/fever onset). Continued surveillance in 2015 identified 16 AFM cases 
reported from 13 states.
Conclusions—Epidemiologic data suggest this AFM cluster was likely associated with the large 
outbreak of EV-D68–associated respiratory illness, although direct laboratory evidence linking 
AFM with EV-D68 remains inconclusive. Continued surveillance will help define the incidence, 
epidemiology, and etiology of AFM.
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Since the widespread implementation of polio vaccination starting in the 1950s, acute 
flaccid paralysis (AFP) due to poliovirus has been eliminated from most countries [1,2]. 
AFP attributable to spinal cord/anterior horn cell involvement (“nonpoliovirus” anterior 
myelitis) is thought to occur infrequently, but various nonpolio enteroviruses (eg, enterovirus 
A71, coxsackie viruses A and B), and other viruses (eg, flaviviruses, herpesviruses, and 
adenoviruses), have occasionally been reported as etiologies [3–5]. AFP incidence in the 
United States population <15 years of age is estimated at around 1.4 cases per 100 000 per 
year [6]; however, systematic surveillance for AFP, specifically with anterior horn cell 
involvement, is not conducted in the United States.
A report at an April 2014 national US neurology meeting of children in California with a 
“polio-like” illness generated substantial media attention [7]. In August 2014, physicians at 
Children’s Hospital Colorado, in Aurora, Colorado, noted an unusual clustering of children 
with acute limb weakness similar to that described in California [8–11]. Most patients had 
distinctive abnormalities of the central spinal cord on magnetic resonance imaging (MRI), 
with gray matter lesions in both anterior and posterior segments of the cord extending 
multiple levels [12]. Based on these clinical and anatomic characteristics, the illness was 
referred to as acute flaccid myelitis (AFM), to distinguish it from other forms of AFP [9]. 
The etiology of the Colorado cases was unclear, although there was a strong temporal 
association with an increase in severe respiratory disease caused by enterovirus D68 (EV-
D68) in Colorado [13]. On 26 September 2014, the Centers for Disease Control and 
Prevention (CDC) issued a health advisory requesting state and local health departments to 
report retrospective and prospective AFM cases and send specimens to CDC for testing 
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(http://emergency.cdc.gov/han/han00370.asp). Here, we summarize the epidemiologic, 
clinical, and laboratory findings of the AFM investigation.
METHODS
Case Information
We defined a case as any person aged ≤21 years, with acute onset of limb weakness starting 
on or after 1 August 2014, and with a spinal MRI revealing lesions predominantly of the 
gray matter. Patients with spinal cord trauma or an otherwise known etiology of limb 
weakness were excluded. Clinicians or public health officials were requested to complete 
and submit a standardized case report form (CRF) (http://www.cdc.gov/acute-flaccid-
myelitis/downloads/patient-summary-form.pdf) including information on patient 
demographics, symptoms (including respiratory illness or documented fever >100.4°F 
(38°C) during the 4 weeks before limb weakness onset), clinical presentation, MRI findings, 
test results from local laboratories, and disposition. We present data for cases with onset 
through 31 December 2014. Denominators vary due to missing data for some questions.
MRI Review
All CRFs were reviewed by 1 of 2 neurologists (D. M. P., J. J. S.); if MRI findings as 
reported on the CRF were ambiguous, a copy of the MRI report was requested. If MRI 
findings remained unclear after review of the report, the MRI images were requested and 
reviewed by one of the study neurologists.
Laboratory Testing
Specimens sent to the CDC included cerebrospinal fluid (CSF), serum (acute and 
convalescent were requested), respiratory samples (nasopharyngeal swab, nasopharyngeal 
aspirate, oropharyngeal swab, or oral swab), and stool (2 stool specimens collected >24 
hours apart, per poliovirus testing protocol) [14]. A diagnostic algorithm was established to 
test for the following pathogens: enteroviruses (enterovirus-specific real-time reverse 
transcription polymerase chain reaction [rRT-PCR]) [15]), EV-D68–specific real-time RT-
PCR (http://www.fda.gov/MedicalDevices/Safety/EmergencySituations/ucm161496.htm) 
and enterovirus typing by VP1 seminested PCR and sequencing [16]; arboviruses (West Nile 
virus [immunoglobulin M {IgM} antibody in CSF or serum by IgM-capture enzyme-linked 
immunosorbent assay {MAC-ELISA}], St Louis encephalitis [IgM antibody in serum by 
microsphere immunoassay], and LaCrosse viruses [IgM antibody in serum by MAC-
ELISA]); herpesviruses (including human herpesviruses 1 and 2, varicella zoster virus, and 
Epstein-Barr virus by fluorescence resonance energy transfer real-time PCR [FRET-rPCR], 
human herpesvirus 6A and 6B by conventional rPCR, and cytomegalovirus by TaqMan 
rPCR); and adenoviruses by rPCR. Expanded viral testing, including a panel of family/genus 
taxon-specific viral PCR assays and sequencing utilizing generic primers for 12 viral 
families and metagenomic next-generation sequencing, was conducted on a subset of cases 
with specimens collected early in the illness. (Full protocols for these CDC in-house PCR 
and serologic methods are available upon request.) Further screening with electron 
microscopy was conducted on a convenience sample of 6 CSF specimens.
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Respiratory Illness Data
Data on respiratory tract specimens testing positive at CDC for EV-D68 were obtained from 
passive national surveillance [13]. We also examined respiratory illness data from BioSense, 
a timely, national electronic health information system operated by CDC and used for 
syndromic surveillance [17, 18]. We used emergency department visits in which dyspnea 
was diagnosed in persons aged <18 years as a syndromic indicator for when peak EV-D68 
circulation occurred nationally in August–October 2014 [13].
Descriptive analyses were performed using SAS version 9.3 software (SAS Institute, Cary, 
North Carolina). The investigation was determined to be nonresearch public health response 
by the CDC Human Subjects Review board.
RESULTS
The CDC received 120 case reports meeting AFM case definition with onset 1 August–31 
December 2014 (Figure 1; Supplementary Figure 1). During the 5-month period, the crude 
nationwide AFM incidence among persons ≤21 years was 0.026 cases per 100 000 
population per month (0.32 cases/100 000 population/year if this monthly rate applied for 12 
months). Cases were reported from 34 states (Figure 2). Median age was 7.1 years (range, 
0.4–20.8 years; interquartile range [IQR], 4.8–12.1 years); 71 (59%) were male (Table 1; 
Supplementary Figure 2). Of 114 patients with information on preceding respiratory illness 
and fever, 64 (56%) had both fever and respiratory symptoms before limb weakness onset, 
28 (25%) experienced only respiratory illness, 10 (9%) experienced only febrile illness, and 
12 (11%) experienced neither. Median interval between respiratory or febrile illness onset 
(whichever occurred first) and limb weakness was 5 days (range, 0–18 days; IQR, 3–9 days).
All but 1 patient was hospitalized (Table 1). Twenty percent of patients required mechanical 
ventilation for neuromuscular respiratory failure. Thirty-four percent had only upper 
extremity involvement, 23% had only lower extremity involvement, and 43% had both upper 
and lower extremities involved. Limb weakness was distinctly asymmetrical in 47%, and 
30% had weakness restricted to 1 limb. Eighty-one percent had decreased or absent deep-
tendon reflexes. Twenty-four percent reported numbness in affected limbs, while 51% 
reported pain. Cranial nerve dysfunction was evident in 28%, including facial weakness 
(14%), dysphagia (12%), and diplopia (9%). Signs suggesting cerebral involvement were 
largely absent, with only 11% demonstrating altered mental status, and 4% with seizures. 
Twenty-one percent with available information reported an underlying medical condition 
prior to onset of neurologic illness; the most frequently reported condition was asthma 
(12/116 [10%]); and 2 patients had an immunosuppressive illness (cardiac transplant and 
diabetes mellitus type 1).
Treatment and Outcomes
Eighty-five of 98 (87%) patients with any treatment information received some type of 
immunomodulating therapy for the neurologic illness, including intravenous 
immunoglobulin (62/85 [73%]), corticosteroids (46 [54%]), plasma exchange (13 [15%]), or 
other immunosuppressive medication (2 [2%]). We received follow-up information from 
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caregivers on the clinical status of 56 (47%) patients, who reported on function (effect of 
limb weakness on daily living activities) and limb strength (Table 1). Median interval 
between limb weakness onset and report of follow-up outcome was 4.2 months (range, 0.8–
7.5 months; IQR, 2.8–5.4 months). Of the 56 respondents, 8 patients (14%) were reported as 
completely dependent on caregivers, 38 (68%) had some degree of functional impairment, 
requiring assistance for some activities, and 10 (18%) reported being fully functional. Only 
3 patients (5%) reported complete recovery of strength; the remainder had some residual 
weakness. There were no deaths.
MRI Findings
Although the entire spinal cord was not imaged in all patients and not all reports included 
details on each level, the most common site of involvement was the cervical spinal cord 
(103/118 [87%]), followed by thoracic (80/100 [80%]) and conus medullaris/cauda equina 
(36/76 [47%]) (Table 2). Spinal cord parenchymal gadolinium enhancement was seen in 22 
of 103 (21%) patients to whom gadolinium was administered, and ventral nerve root 
enhancement was visualized in 16 of 47 (34%) patients with MRI imaging of the cauda 
equina and were administered gadolinium. Ninety-seven of 101 (96%) patients whose report 
included the affected spinal cord levels had >1 spinal segment involved.
CSF Characteristics
One hundred twelve patients had CSF parameters reported. The median interval between 
limb weakness onset and CSF collection was 2 days (range, 0–42 days; IQR, 1–3 days); 
another 5 patients had CSF collected before their limb weakness onset. Median CSF white 
blood cell (WBC) count was 44 cells/μL (range, 0–664 cells/μL; IQR, 12–93 cells/μL; 
Supplementary Table 1). CSF pleocytosis, defined as WBC >5 cells/μL, was present in 91 
cases (81%), with most having lymphocytic predominance. Median CSF protein and glucose 
were 43 (range, 17–921; IQR, 34–60) mg/dL and 59 (range, 37–154; IQR, 53–68) mg/dL, 
respectively (referent normal values: CSF protein <45 mg/dL; CSF glucose ≥40 mg/dL).
CDC Laboratory Results
CDC laboratories tested CSF from 55 patients (Table 3; Supplementary Figure 3). The 
median duration between respiratory/febrile illness onset and CSF collection (earliest 
sample if >1 from a patient) was 7.5 days (IQR, 5–13 days) (Supplementary Figure 4). One 
CSF specimen tested positive for EV-D68 by rRT-PCR, as well as for Epstein-Barr virus by 
FRET-rPCR; however, this specimen had >3000 red blood cells/μL, and no corresponding 
blood sample was available to clarify whether virus was present in blood. No other CSF 
specimens tested at CDC using pathogen-specific primers or serologic assays produced a 
positive result. Of 35 CSF specimens tested by metagenomic sequencing, 14 resulted in 
detection of several different viruses unlikely to be of clinical significance (Table 3). No 
pathogens were detected in the 6 CSF specimens examined by electron microscopy.
Using the earliest respiratory specimen for 56 patients that submitted at least 1 specimen, 11 
(20%) nasopharyngeal/oropharyngeal specimens were positive for EV-D68 (includes 
patients from 6 different states), and 12 (21%) were positive for other enteroviruses/
rhinoviruses (Table 3; Supplementary Tables 2 and 3). The proportion positive for EV-D68 
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increased in specimens collected closer to onset of respiratory/febrile illness, with 47% 
(8/17) of respiratory specimens collected ≤7 days from respiratory/febrile illness onset 
positive for EV-D68 (Supplementary Table 3). All serum/plasma specimens from 43 patients 
tested negative for enteroviruses by RT-PCR (Table 3). None of the 35 sera tested positive 
for IgM antibodies against arboviruses (West Nile, LaCrosse, St Louis encephalitis). None of 
the 54 stool/rectal swab specimens tested positive for poliovirus by culture or rRT-PCR; EV-
D68 was also not detected in stool (Table 3; Supplementary Tables 4 and 5). By family/
genus taxon-specific viral PCRs of specimens other than CSF, a few viruses were detected in 
low frequency.
External Laboratory Results
The reported number of tests conducted on each specimen in laboratories outside of CDC 
(eg, hospitals, independent clinical laboratories, state laboratories) varied. Three patients 
were reported to have viral RNA/DNA detected in CSF: 1 each with cytomegalovirus, 
echovirus 11, and human parechovirus. Among all specific viral testing results reported from 
any specimen type, only EVD-68 (in respiratory specimens from 8 patients) was detected in 
≥2 patients (Supplementary Table 6).
Correlation With National Respiratory Illness
The majority of cases (97 [81%]) experienced limb weakness onset during 1 August–31 
October 2014, with peak onset in mid/late September. This coincides with the increase and 
peak in pediatric emergency department visits for dyspnea collected in BioSense, as well as 
the number of respiratory samples sent from states to CDC for EV-D68 testing and the 
proportion testing positive (Figure 1).
DISCUSSION
We report 120 cases of pediatric AFM, most occurring during a national outbreak of EV-
D68–associated respiratory illness. Neurologic illness was characterized by asymmetric 
flaccid limb weakness and spinal MRI findings showing gray matter involvement. Among 
those with follow-up information, most made some recovery, but few a full recovery. This 
clinical and neuroimaging phenotype is identical to that observed with poliovirus-associated 
acute paralysis. No pathogens were consistently detected in CSF or serum.
AFM cases were tightly clustered in time, and anecdotally, clinicians from several locations 
stated that the number of AFM cases observed over the 5-month period was unprecedented 
in their experience. However, we cannot confirm whether there was truly an increase in 
cases over previous years, as surveillance for neither AFM nor AFP is routinely conducted 
in the United States.
Since the elimination of wild-type poliovirus from the Western Hemisphere in 1991 [19], 
most AFP cases among all ages worldwide have been attributable to Guillain-Barré 
syndrome, an immune-mediated condition affecting peripheral nerves and nerve roots (not 
spinal gray matter). There are other recognized etiologies of AFP, and specifically AFM, 
including nonpolio enteroviruses [20–22], flaviviruses such as West Nile, St Louis, and 
Japanese encephalitis viruses [4, 23, 24], herpesviruses [25, 26], adenoviruses [27, 28], and 
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others [3]. Although these pathogens may also be associated with other forms of AFP, 
including Guillain-Barré syndrome and acute transverse myelitis, AFM caused by these 
pathogens usually occurs sporadically, with the exception of EV-A71 outbreaks in East Asia 
[29, 30]. An estimate of the incidence of nonpoliovirus AFM, however, is hampered by lack 
of systematic surveillance and laboratory testing.
In late summer and early fall 2014, clinicians throughout the country noted an increase in 
hospitalizations for severe respiratory illness among children, suspected to be associated 
with EV-D68 [13, 31]. Outbreaks of EV-D68–associated respiratory illness were also 
reported in other countries in 2014 [32–37]. We demonstrated in several states with 
BioSense data that the occurrence of AFM aligned with the increase in pediatric emergency 
department visits for dyspnea and few AFM cases occurred after dyspnea visits declined by 
early October 2014. We continued to conduct AFM surveillance in 2015, and from 1 January 
through 31 December, 16 individuals meeting the 2014 case definition were reported from 
13 states; 9 cases occurred from August through December. Moreover, passive surveillance 
at CDC did not identify any cases of EV-D68 respiratory illness in 2015. This temporal 
association between AFM and EV-D68 respiratory illness in 2014, and the lack of both in 
2015, may suggest a causal association, although the association is ecological and 
surveillance was only done for 2 enterovirus seasons [8, 38].
There is biological plausibility to support such a causal association—other enteroviruses are 
recognized to cause AFM, most notably poliovirus and enterovirus-A71 [39, 40]. Moreover, 
EV-D68 has been detected in the CSF of a child with fatal meningomyeloencephalitis, as 
well as in the blood and upper respiratory tract of patients with AFM [35, 38, 41, 42]. 
However, despite testing of numerous CSF specimens as part of our national investigation 
(Supplementary Figure 2), we identified only 1 case with EV-D68 nucleic acid in the CSF, 
suggesting the presence of the virus within the intrathecal space. However, given the 
presence of red blood cells in the CSF, it is possible that the blood was the source of the EV-
D68 (ie, from a presumptive viremia). Experience with other viruses that cause AFM 
suggests that while identification of intrathecal presence of virus by culture or PCR is 
difficult, a certain percentage of cases would be expected to test positive [43–46]. The 
detection of EV-D68 in CSF could have been hampered by delayed timing of specimen 
collection in relation to direct viral neuronal invasion and/or the relatively small number of 
samples to detect a transient presence of virus in CSF. Alternatively, neuronal damage could 
have been due to a postinfectious immune response; inflammatory damage to gray matter, 
although less common than to white matter, has increasingly been described in other 
syndromes [47–49].
While overall only 20% of patients had EV-D68 detected in upper respiratory tract 
specimens, it is possible that because of the long interval between respiratory illness onset 
and specimen collection, the virus could no longer be detected; among respiratory specimens 
collected ≤7 days after respiratory illness/fever onset, 47% were positive for EV-D68. 
However, detection of viruses in nonsterile sites, such as the upper respiratory tract, in AFM 
patients has unclear etiologic significance. The lack of EV-D68 in the stool has been shown 
before [50].
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Possibly EV-D68 is “necessary but not sufficient” in the pathogenesis of AFM, rather than 
being truly neuroinvasive, and that other unknown factors, along with EV-D68 infection, are 
necessary to cause AFM. While the possibility of an autoimmune etiology has also been 
raised, the clinical and neuroradiographic findings are more consistent with a neuroinvasive 
viral pathogen. This is suggested by the abrupt limb weakness onset, the predominance of 
gray (rather than white) matter involvement, and the apparent lack of response to 
immunosuppressive therapy or significant improvement of neurologic deficits over time [51–
53].
Our investigation has several limitations. We utilized a very specific case definition, 
including MRI findings, to ensure that we identified cases with the same disease process. 
However, we might have missed some true cases not meeting our strict case definition, 
underestimating the true illness burden. Several cases reported from Colorado presented 
with cranial nerve deficits alone [8]; as we limited our surveillance to patients with limb 
weakness, we would have failed to identify other possible neurologic manifestations of this 
syndrome. Second, we received CSF specimens for testing at CDC on only 46% of AFM 
cases. In some cases, timing of specimen collection may not have been optimal to 
conclusively rule in or rule out particular etiologies (eg, arboviral serologies). Finally, 
follow-up information was available only on about one-half of patients, and the 
representativeness of those outcomes is not known.
In the future, it will be important for clinicians to maintain vigilance for AFM and report 
cases to public health officials, both to better ascertain background incidence of this 
syndrome and to provide early detection of large outbreak events. Application of new 
laboratory diagnostic techniques may allow for determination of causative etiologies for 
AFM. Furthermore, as poliovirus is an important cause of AFM globally, it is critical to 
document that polio has been ruled out with the involvement of the state/local health 
department. Documentation should include appropriate specimens for viral isolation, 
documented poliovirus vaccine history, travel history, or exposure to someone who may have 
traveled, and 60-day follow-up of the neurologic deficit (http://www.cdc.gov/vaccines/pubs/
surv-manual/chpt12-polio.html). Collection of appropriate biological specimens as early as 
possible will facilitate identification of an etiology of AFM. Cooperation between clinicians 
and public health officials will be important to better understand the epidemiology and 
clinical features of AFM.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Number of acute flaccid myelitis (AFM) cases by week of limb weakness onset (A), 
dyspnea visits at hospital emergency departments among children aged <18 years (B), and 
respiratory specimens tested for enterovirus D68 (EV-D68) at the Centers for Disease 
Control and Prevention (CDC) by week of sample collection (C), United States, 1 June–31 
December 2014. B, BioSense data are combined from 24 states that reported at least 1 AFM 
case and whose BioSense data (>90% of emergency department visits) came from hospitals 
that contributed consistently during August–October 2014. BioSense hospitals may be 
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different from the hospitals that reported AFM cases. C, First public health communication 
informing states that CDC was available to test respiratory specimens for EV-D68 was on 28 
August 2014. On 25 September 2014, CDC communications stated that CDC testing would 
be prioritized to samples from children with severe respiratory disease. Over time, more 
state laboratories developed capacity to test their samples.
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Figure 2. 
State distribution of acute flaccid myelitis (AFM) cases, United States, August–December 
2014 (N = 120).
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Table 1
Demographics and Clinical Findings Among Acute Flaccid Myelitis Cases, United States, August–December 
2014 (N = 120)
Variable (No. With Information) No. (%)
At time of acute illness
 Age, median (range; IQR) (n = 119) 7.1 y (0.4–20.8 y; 4.8–12.1 y)
 Sex (n = 120)
  Male 71 (59)
  Female 49 (41)
 Race (n = 95)
  American Indian or Alaska Native 1 (1)
  Asian 8(8)
  Black or African American 7 (7)
  Native Hawaiian or Pacific Islander 0(0)
  White 79 (83)
 Ethnicity (n = 88)
  Hispanic or Latino 29 (33)
  Not Hispanic or Latino 59 (67)
 Hospitalized (n = 119) 118 (99)
 Respiratory illness preceding limb weakness (n = 118) 95 (81)
 Febrile illness preceding limb weakness (n = 115) 74 (64)
 Respiratory or febrile illness preceding limb weakness (n = 117) 105 (90)
 Limb involvement (n = 119)a
  Upper extremity(ies) only 41 (34)
  Lower extremity(ies) only 27 (23)
  Upperand lowerextremities, but not all 4 extremities 21 (18)
  All 4 extremities involved 30 (25)
 Cranial nerve findings (n = 120)
  Any cranial nerve sign 34 (28)
  Facial weakness 17 (14)
  Dysphagia 14 (12)
  Diplopia/double vision 10 (9)
  Dysarthria 8(7)
  Facial numbness 1 (1)
 Altered mental status (n = 109) 12 (11)
 Seizures during illness (n = 116) 5(4)
 Received care in intensive care unit (n = 112) 58 (52)
 Required mechanical ventilation (n = 109) 26 (20)
 Underlying illness (n = 116) 24 (21)
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Variable (No. With Information) No. (%)
  Asthmab 12 (10)
  Otherc 12 (10)
At time of follow-up (median 4.2 mo after acute illness) 56 (49)
 Functiond
  Complete dependence on caretakers 8 (14)
  Somewhat functionally impaired 38 (68)
  Fully functional 10 (18)
 Strength (compared to initial presentation)
 As weak 11 (20)
  Some improvement 41 (73)
  Full recovery 3 (5)
  More weak 1 (2)
Abbreviation: IQR, interquartile range.
a
Remaining case had both lower extremities involved, but information was not provided on upper extremities.
bOne of these cases with asthma was also a former premature infant (26 weeks’ gestation).
cCardiac transplant on immunosuppressive therapy, diabetes mellitus type 1, cerebral palsy with hemiplegia, failure to thrive, post–spinal fusion 
surgery for scoliosis, postsurgery for Hirschprung disease, former premature infant (32 weeks’ gestation), G6PD deficiency (n = 1 each), attention 
deficit disorder (n = 4) (categories are all exclusive).
d
Effect of limb weakness on activities of daily living.
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Table 2
Magnetic Resonance Imaging Findings Among Acute Flaccid Myelitis Cases, United States, August–
December 2014 (N = 120)
Finding No. of Patients (%)a
MRI of spinal cord performed
 Cervical cord involvement 103/118 (87)a
 Thoracic cord involvement
  80/100 (80)a
 Conus–cauda equina involvement
    36/76 (47)a
 Ventral nerve enhancement
    16/47 (34)b
MRI of brain performed
 Cerebral lesions/brain MRI performed 11/104 (11)
 Cerebellar lesions/brain MRI performed 11/104 (11)
 Brainstem lesions/brain MRI performed 36/104 (35)
 Pontine lesions/number with brainstem lesions   28/36 (78)
 Medulla lesions/number with brainstem lesions   27/36 (75)
 Midbrain lesions/number with brainstem lesions   10/36 (28)
a
Denominator is number of patients reported having that spinal cord level imaged and result provided.
b
Denominator is number of patients reported having lumbosacral MRI performed, gadolinium administered, and result provided.
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Table 3
Laboratory Results, Centers for Disease Control and Prevention Laboratories
Pathogens CSF Respiratory Serum/Plasma Stool/Rectal Swab
Enterovirus/rhinovirus   1/55 (2) 24/56 (43)a 0/43 (0) 11/54b (20)
 EV-D68     1/1 (100) 11/23 (48)   …     0/11 (0)
 Non-EV-D68     0/1 (0) 12/23 (52)   …   11/11 (100)
Adenoviruses   0/48 (0)   0/44 (0) 1/39 (3)     5/47 (11)
Herpesviruses
 Herpes simplex virus 1   0/41 (0)   0/35 (0) 0/33 (0)   …
 Herpes simplex virus 2   0/41 (0)   0/35 (0) 0/33 (0)   …
 Varicella zoster virus   0/41 (0)   0/35 (0) 0/33 (0)   …
 Epstein-Barr virus   1/41 (2)   3/35 (9) 2/31 (6)   …
 Human herpesvirus 6A   0/39 (0)   … 0/29 (0)   …
 Human herpesvirus 6B   0/39 (0)   … 0/29 (0)   …
 Cytomegalovirus   0/38 (0)   … 0/26 (0)   …
Panviral PCR platform   0/31 (0)
    2/9 (22)c 1/16 (6)d     1/7 (14)e
Metagenomic next-generation sequencing 14/35 (40)f     1/1 (100)g 7/12 (54)h   …
Arboviruses (IgM)
 West Nile     0/2 (0)   … 0/35 (0)i   …
 St Louis encephalitis     0/2 (0)   … 0/35 (0)i   …
 La Crosse     0/4 (0)   … 0/35 (0)i   …
Data are presented as No. positive/No. tested (% positive).
Abbreviations: …, no specimens tested; CSF, cerebrospinal fluid; EV, enterovirus; IgM, immunoglobulin M; PCR, polymerase chain reaction.
aOne was enterovirus/rhinovirus (EV/RV) positive but untypeable.
bOne specimen collected about 2 weeks before the onset of limb weakness, respiratory illness, and fever is not included in this denominator. It was 
negative for EV/RV.
c
Herpesviridae (human herpesvirus 7, n = 1) and Herpesviridae (human herpesvirus 6a/b, n = 1).
d
Parvoviridae (erythrovirus B19, n = 1).
e
Parvoviridae (mouse PV, n = 1).
fGB virus C (n = 8), human rhinovirus 4 (n = 4), transfusion transmitted virus (TTV) (n = 1), GB virus C, and TTV-like mini virus (n = 1).
gGB virus C and EV-D68 (n = 1) (by EV/RV real-time reverse transcription polymerase chain reaction, only human rhinovirus A24 was detected in 
the specimen and hence this specimen is counted as EV-D68 negative in all the calculations in the manuscript).
hGB virus C (n = 6), GB virus C, and TTV-like mini virus (n = 1).
i
Thirty-three patients with 1 serum specimen only: timing of serum collection from limb weakness onset: <3 days, n = 8; 3–10 days, n = 14; ≥11 
days, n = 9; unknown, n = 2; 1 patient with serum 2 and 12 days after onset; 1 patient with serum 22 and 43 days after onset.
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